Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Clinical Research and Equipment Industry Analysis

UpdatedApr 14, 2026
DataAggregated Company Financials
Companies61
  • 7D3.5%
  • 3M-17.9%
  • 1Y9.2%
  • YTDn/a

The Clinical Research and Equipment industry has stayed flat over the last week. As for the the longer term, the industry is up 7.5% over the past 12 months. Earnings are forecast to grow by 18% annually.

Industry Valuation and Performance

Has the U.S. Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 14 Apr 2026US$562.8bUS$147.8bUS$14.1b37.9x39.9x3.8x
Thu, 12 Mar 2026US$564.2bUS$147.8bUS$14.0b33.8x40.3x3.8x
Sat, 07 Feb 2026US$613.7bUS$147.4bUS$12.9b36.4x47.7x4.2x
Mon, 05 Jan 2026US$667.9bUS$145.8bUS$12.4b36.1x54x4.6x
Wed, 03 Dec 2025US$666.1bUS$145.8bUS$12.5b36.6x53.4x4.6x
Fri, 31 Oct 2025US$637.0bUS$145.4bUS$12.7b35.5x50.1x4.4x
Sun, 28 Sep 2025US$552.3bUS$144.3bUS$14.6b29.4x37.9x3.8x
Tue, 26 Aug 2025US$588.7bUS$144.1bUS$14.5b29x40.6x4.1x
Thu, 24 Jul 2025US$540.0bUS$143.4bUS$8.7b37.3x62.2x3.8x
Sat, 21 Jun 2025US$516.2bUS$142.9bUS$9.2b35.3x56.3x3.6x
Mon, 19 May 2025US$519.4bUS$142.7bUS$9.1b33.3x57.1x3.6x
Wed, 16 Apr 2025US$525.4bUS$142.6bUS$10.0b34.8x52.8x3.7x
Fri, 14 Mar 2025US$587.4bUS$143.1bUS$9.8b37.4x60.2x4.1x
Sun, 09 Feb 2025US$658.3bUS$143.1bUS$11.1b38.1x59.3x4.6x
Tue, 07 Jan 2025US$665.5bUS$142.4bUS$10.2b43.7x65.2x4.7x
Thu, 05 Dec 2024US$673.5bUS$142.4bUS$10.2b44.4x65.9x4.7x
Sat, 02 Nov 2024US$672.6bUS$142.2bUS$8.9b39.1x75.4x4.7x
Mon, 30 Sep 2024US$748.6bUS$141.8bUS$8.5b40.1x88.1x5.3x
Wed, 28 Aug 2024US$740.9bUS$141.8bUS$8.5b37.8x87.2x5.2x
Fri, 26 Jul 2024US$709.8bUS$141.1bUS$12.5b36.3x56.7x5x
Sun, 23 Jun 2024US$694.3bUS$141.3bUS$12.2b38.6x57x4.9x
Tue, 21 May 2024US$741.0bUS$141.5bUS$12.4b38.6x59.6x5.2x
Thu, 18 Apr 2024US$690.2bUS$142.0bUS$12.8b41.9x54x4.9x
Sat, 16 Mar 2024US$745.1bUS$142.1bUS$12.8b43.9x58x5.2x
Mon, 12 Feb 2024US$708.4bUS$141.9bUS$12.7b39.7x55.7x5x
Wed, 10 Jan 2024US$692.8bUS$153.8bUS$14.2b36.3x48.9x4.5x
Fri, 08 Dec 2023US$648.0bUS$153.7bUS$14.0b35.2x46.3x4.2x
Sun, 05 Nov 2023US$597.4bUS$153.9bUS$11.0b31.5x54.2x3.9x
Tue, 03 Oct 2023US$672.6bUS$154.6bUS$11.2b32.9x60x4.4x
Thu, 31 Aug 2023US$736.8bUS$154.6bUS$11.2b33.5x65.7x4.8x
Sat, 29 Jul 2023US$734.3bUS$154.7bUS$11.6b31.5x63.2x4.7x
Mon, 26 Jun 2023US$690.9bUS$152.4bUS$12.5b29.3x55.3x4.5x
Wed, 24 May 2023US$684.3bUS$152.1bUS$12.5b29x54.9x4.5x
Fri, 21 Apr 2023US$718.9bUS$154.6bUS$10.8b29.4x66.5x4.7x
Price to Earnings Ratio

66.5x


Total Market Cap: US$718.9bTotal Earnings: US$10.8bTotal Revenue: US$154.6bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Clinical Research and Equipment Industry Price to Earnings3Y Average 57.4x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 39.8x which is lower than its 3-year average PE of 57.4x.
  • The 3-year average PS ratio of 4.5x is higher than the industry's current PS ratio of 3.8x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have grown 9.3% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Comparison

How does U.S. Clinical Research and Equipment compare with similar industries?

US Market4.25%
Healthcare1.57%
Life Sciences3.46%
Clinical Research and Equipment3.46%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TMO Thermo Fisher ScientificUS$514.235.3%
+US$9.7b		14.4%PE28.5x
DHR DanaherUS$195.872.0%
+US$2.7b		1.5%PE38.5x
WAT WatersUS$324.686.8%
+US$2.0b		-2.7%PE49.6x
MTD Mettler-Toledo InternationalUS$1.35k6.3%
+US$1.6b		24.3%PE31.4x
A Agilent TechnologiesUS$117.502.3%
+US$751.7m		11.7%PE25.7x

Latest News

TEM
US$45.98
Tempus AI
7D
-2.8%
1Y
6.6%
RVTY
US$92.64
Revvity
7D
4.9%
1Y
-5.1%
WAT
US$324.68
Waters
7D
6.8%
1Y
-2.7%
QTRX
US$3.39
Quanterix
7D
-5.8%
1Y
-39.5%

Quanterix: No Green Shoots

Apr 10
MTD
US$1,345.89
Mettler-Toledo International
7D
6.3%
1Y
24.3%

MTD: Extensive Buybacks And 2026 Sales Outlook Will Support Future Upside

Analysts have trimmed their price target for Mettler-Toledo International by about $7 to $1,498, reflecting small adjustments to fair value, discount rate, revenue growth and profit margin assumptions, along with a slightly lower future P/E estimate. What's in the News Mettler-Toledo International reported completion of a long running share repurchase program first announced on February 9, 2010, having bought back a total of 17,805,987 shares, or 66.06%, for US$9,514.61m under the authorization.
DNA
US$6.68
Ginkgo Bioworks Holdings
7D
-2.8%
1Y
-20.1%

DNA: Biosecurity Exit And Cash Burn Will Pressure Autonomous Lab Payoff

Analysts have reduced their price target on Ginkgo Bioworks Holdings to $5 from $9, citing the sale of the biosecurity business and a desire for clearer progress on building and monetizing autonomous labs as key reasons for the reset. Analyst Commentary Bearish analysts are signaling a more cautious stance on Ginkgo Bioworks Holdings following the reduction in the price target to US$5 from US$9.
NAUT
US$2.97
Nautilus Biotechnology
7D
-11.3%
1Y
279.7%
A
US$117.50
Agilent Technologies
7D
2.3%
1Y
11.7%

A: New Diagnostic Expansion And Guidance Will Support Long Term Upside

Analysts have slightly reduced their price target on Agilent Technologies by about $1, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. They indicate that the overall outlook remains largely intact.
TMO
US$514.23
Thermo Fisher Scientific
7D
5.3%
1Y
14.4%
OABI
US$1.46
OmniAb
7D
-5.2%
1Y
-24.4%

OABI: Updated Bylaws And 2026 Revenue Guidance Will Support Long Term Upside

Analysts kept their price target on OmniAb broadly aligned with prior views, citing relatively steady assumptions around fair value, growth and profitability that offset only minor tweaks to the discount rate and future P/E multiple. What's in the News OmniAb issued earnings guidance for 2026, with expected revenue in a range of $25 million to $30 million, giving you a reference point for the company’s own outlook on its top line for that year (Key Developments).
CRL
US$178.34
Charles River Laboratories International
7D
6.0%
1Y
67.3%

CRL: Improving Book To Bill And Higher Margins Will Support Future Upside

The updated analyst price target for Charles River Laboratories International has moved higher to reflect a fair value estimate of about $262, as analysts factor in a lower assumed future P/E of roughly 28x, more conservative revenue growth near 3%, and higher projected profit margins of about 13% following recent research that includes both target hikes and cuts across the Street. Analyst Commentary Street research on Charles River Laboratories International has been active, with several firms adjusting price targets and highlighting both company specific and sector related factors.
DHR
US$195.87
Danaher
7D
2.0%
1Y
1.5%

Danaher: A Great Way To Play Healthcare For Long-Term Dividend Growth Investors

Apr 06
TECH
US$57.53
Bio-Techne
7D
6.9%
1Y
9.5%

TECH: Clinical And Spatial Biology Platforms Will Support Higher Future Earnings Multiple

Analysts have trimmed their price target on Bio-Techne to about $65, with updated assumptions reflecting slightly adjusted discount rates, revenue growth expectations, profit margins, and a modest shift in projected future P/E levels. What's in the News Expanded COMET spatial biology portfolio with new SPYRE Focus Panels and SPYRE Amplification Kits, plus updated HORIZON Image Analysis Software to support more flexible and sensitive tissue analysis workflows (Key Developments).
PSNL
US$6.31
Personalis
7D
-4.1%
1Y
94.8%
ATLN
US$2.97
Atlantic International
7D
-11.1%
1Y
-19.1%
LAB
US$0.88
Standard BioTools
7D
-4.6%
1Y
-23.3%

LAB: Share Buybacks And Steady Outlook Will Support Future Upside

Analysts now see fair value for Standard BioTools holding at $1.35 per share, with a slightly higher discount rate and P/E assumptions, and a less steep projected revenue contraction supporting a steady price target despite mixed tweaks to the model inputs. What's in the News Standard BioTools completed a share repurchase program covering 13,603,617 shares, equal to 7.63% of the company, for a total of $35.91 million under the buyback announced on March 1, 2024 (Key Developments).